Register Login

AVALYN PHARMA INC. (AVLN)

(30% Negative) AVALYN PHARMA INC. (AVLN) Announces Delay in investigator Trials for lung function Due to Patient Enrollment Issues, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot June 17, 2026, 12:04 p.m.

    📋 AVALYN PHARMA INC. (AVLN) - Clinical Trial Update

    Filing Date: 2026-06-17

    Accepted: 2026-06-17 08:03:19

    Event Type: Clinical Trial Update

    Event Details:

    AVALYN PHARMA INC. (AVLN) Announces Clinical Trial Update AVALYN PHARMA INC. (AVLN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: investigator, decline
    • Diseases/Conditions: lung function
    • Clinical Stage: clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment
    • Collaboration: Company

    🔬 Clinical Development Pipeline (AVALYN PHARMA INC.):

    Product Type Development Stage Therapeutic Area Source
    AP01 Other Phase PHASE2 Progressive Pulmonary Fibrosis ClinicalTrials.gov
    AP02 Other Phase PHASE2 Idiopathic Pulmonary Fibrosis (IPF) ClinicalTrials.gov
    Placebo Other Phase PHASE2 Idiopathic Pulmonary Fibrosis (IPF) ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: AVALYN PHARMA INC.
    • Ticker Symbol: AVLN

Search

News categories